Medicenna Therapeutics is an immunotherapy company focused on oncology. It develops and commercializes selective versions of IL-2, IL-4, and IL-13 Superkines and Empowered Cytokines (ECs) for the treatment of a range of cancers. The company offers a technology platform that delivers potent cell-killing agents for cancer as well as actively alters the immunosuppressive tumor micro-environment without harming healthy cells.